Zomedica Corp. (ZOMDF)

Healthcare · OQB

$0.08+2.56% today

Price as at 1 Oct 2026, 04:11 UTC. Quotes are delayed.

Fundamentals

Market cap$88.20M
Revenue growth (YoY)+35.4%
Profit margin-65.8%
Return on equity-18.6%
52-week range$0.06 to $0.16

Valuation and ratings

Fair value estimate$0.12
Upside to fair value+50.0%
Moat score45/100
Overall rating58/100, good quality

Fair value: $0.12 (+50.0%), see how we got there

Zomedica Corp. trades at $0.08, which is 50% below the $0.12 our fair value estimate puts on the business. On that measure alone it screens as undervalued, though a valuation model is an argument rather than a measurement, and the market is frequently right about why something is cheap.

Our moat model scores it 45 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.

About Zomedica Corp.

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. It offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. The company provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, Assisi EquiLoop, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

Industry: Medical DevicesEmployees: 141HQ: United States

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

ZOMDF passes 3 of our 30 screens today

Each screen prints the exact criteria it used, and the circumstances in which it is wrong.

ZOMDF peers

The largest companies in the same industry (Medical Devices), then in the same sector.

Every healthcare company we cover is on the Healthcare hub.

Common questions

Is Zomedica Corp. (ZOMDF) undervalued?

Against our fair value estimate of $0.12, ZOMDF at $0.08 is 50% below fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.

Where does SteadyShares get its ZOMDF data?

Fundamentals for ZOMDF come from company filings and exchange data, as listed on OQB; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 04:11 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.

The full research page for ZOMDF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.

Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.